Literature DB >> 17723166

Emerging roles of deubiquitinating enzymes in human cancer.

Jin-ming Yang1.   

Abstract

Protein modifications by the covalent linkage of ubiquitin have significant involvement in many cellular processes, including stress response, oncogenesis, viral infection, transcription, protein turnover, organelle biogenesis, DNA repair, cellular differentiation, and cell cycle control. Protein ubiquitination and subsequent degradation by the proteasome require the participation of both ubiquitinating enzymes and deubiquitinating enzymes. Although deubiquitinating enzymes constitute a large family in the ubiquitin system, the study of this class of proteins is still in its infant stage. Recent studies have revealed a variety of molecular and biological functions of deubiquitinating enzymes and their association with human diseases. In this review we will discuss the possible roles that deubiquitinating enzymes may play in cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17723166     DOI: 10.1111/j.1745-7254.2007.00687.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  11 in total

Review 1.  DUBs at a glance.

Authors:  Keith D Wilkinson
Journal:  J Cell Sci       Date:  2009-07-15       Impact factor: 5.285

2.  HAUSP regulates c-MYC expression via de-ubiquitination of TRRAP.

Authors:  Seemana Bhattacharya; Mrinal K Ghosh
Journal:  Cell Oncol (Dordr)       Date:  2015-04-30       Impact factor: 6.730

3.  The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.

Authors:  Sanguine Byun; Seung Ho Shin; Eunjung Lee; Jihoon Lee; Sung-Young Lee; Lee Farrand; Sung Keun Jung; Yong-Yeon Cho; Soo-Jong Um; Hong-Sig Sin; Youn-Ja Kwon; Chengjuan Zhang; Benjamin K Tsang; Ann M Bode; Hyong Joo Lee; Ki Won Lee; Zigang Dong
Journal:  Carcinogenesis       Date:  2015-10-13       Impact factor: 4.944

4.  UCH-L1 involved in regulating the degradation of EGFR and promoting malignant properties in drug-resistant breast cancer.

Authors:  Yiting Jin; Wei Zhang; Jiawen Xu; Hongying Wang; Zijing Zhang; Chengyu Chu; Xiuping Liu; Qiang Zou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  USP8 is a novel target for overcoming gefitinib resistance in lung cancer.

Authors:  Sanguine Byun; Sung-Young Lee; Jihoon Lee; Chul-Ho Jeong; Lee Farrand; Semi Lim; Kanamata Reddy; Ji Young Kim; Mee-Hyun Lee; Hyong Joo Lee; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  Clin Cancer Res       Date:  2013-06-07       Impact factor: 12.531

6.  Over-expression of ubiquitin carboxy terminal hydrolase-L1 induces apoptosis in breast cancer cells.

Authors:  Wen-Juan Wang; Qing-Quan Li; Jing-Da Xu; Xi-Xi Cao; Hai-Xia Li; Feng Tang; Qi Chen; Jin-Ming Yang; Zu-De Xu; Xiu-Ping Liu
Journal:  Int J Oncol       Date:  2008-11       Impact factor: 5.650

7.  BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.

Authors:  Karen H Ventii; Narra S Devi; Kenneth L Friedrich; Tatiana A Chernova; Mourad Tighiouart; Erwin G Van Meir; Keith D Wilkinson
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

8.  Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer.

Authors:  Marlena S Fejzo; Lee Anderson; Erika M von Euw; Ondrej Kalous; Nuraly K Avliyakulov; Michael J Haykinson; Gottfried E Konecny; Richard S Finn; Dennis J Slamon
Journal:  Int J Mol Sci       Date:  2013-02-01       Impact factor: 5.923

9.  A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumours.

Authors:  A P Carneiro; C F Reis; E C Morari; Y C P Maia; R Nascimento; J M C Bonatto; M A de Souza; L R Goulart; L S Ward
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640

10.  Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer.

Authors:  Thomas S Dexheimer; Andrew S Rosenthal; Diane K Luci; Qin Liang; Mark A Villamil; Junjun Chen; Hongmao Sun; Edward H Kerns; Anton Simeonov; Ajit Jadhav; Zhihao Zhuang; David J Maloney
Journal:  J Med Chem       Date:  2014-09-17       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.